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Summary 
Self-propagating amyloid- (Aaggregates or seeds possibly drive 
pathogenesis of Alzheimer’s disease (AD). Small molecules targeting such structures 
might act therapeutically in vivo. Here, a fluorescence polarization (FP) assay was 
established that enables the detection of compound effects on both seeded and 
spontaneous A42 aggregation. In a focused screen of anti-amyloid compounds, we 
identified DO1 [4-((4-nitrophenyl)diazenyl)-N-phenylaniline], a small molecule that 
potently delays both seeded and non-seeded A42 polymerization at 
substoichiometric concentrations. Mechanistic studies revealed that DO1 disrupts 
preformed fibrillar assemblies of synthetic A42 peptides and decreases the seeding 
activity of Aaggregates from brain extracts of AD transgenic mice. DO1 also 
reduced the size and abundance of diffuse A plaques and decreased 
neuroinflammation-related gene expression changes in brains of 5xFAD transgenic 
mice. Finally, improved nesting behavior was observed upon treatment with the 
compound. Together, our evidence supports targeting of self-propagating A 
structures with small molecules as a valid therapeutic strategy. 
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Introduction 
Alzheimer’s disease (AD) is a late onset progressive disorder characterized by 
memory loss and severe personality changes (Masters et al., 2015). In 2015, an 
estimated 23-33 million patients suffered from this most common form of dementia 
worldwide. Numbers are likely to double, if not treble, by 2050 (Winblad et al., 2016), 
unless effective, disease-modifying therapies that halt or delay progression become 
available. 
The deposition of amyloid- (A) peptides in large, insoluble extracellular 
amyloid plaques is a pathological hallmark of AD (Masters et al., 2015; Selkoe and 
Hardy, 2016). Studies over the past decades, however, have suggested that small, 
soluble A aggregates might also be relevant for neuronal toxicity and disease 
(Benilova et al., 2012). Such highly dynamic structures, detectable with biochemical 
methods and conformation-specific antibodies in brains of patients and AD 
transgenic mice, have been demonstrated to cause dysfunction and toxicity in 
various cellular models (Walsh et al., 2002). Recently, experimental evidence was 
provided that structural variants of fibrillar A aggregates prepared from patient 
brains correlate with specific clinical subtypes (Qiang et al., 2017). In transgenic 
mice, these aggregates act as templates that can convert A peptides from a soluble 
to an aggregated state (Jucker and Walker, 2013). This phenomenon, often termed 
“seeding” or “self-propagation”, was studied in vivo, in brains of AD transgenic mice 
(Meyer-Luehmann et al., 2006) and in vitro, using protein misfolding cyclic 
amplification (PMCA) assays (Salvadores et al., 2014). Experimental evidence 
suggests that fibrillar A aggregates with seeding activity might be a promising 
therapeutic target for AD. Small molecules that directly bind to such structures and 
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inhibit their seeding activity might have high potential to reduce symptoms in model 
organisms and patients. 
A variety of small molecules have been described to directly target 
amyloidogenic A peptides and interfere with their spontaneous self-assembly into -
sheet-rich, fibrillar aggregates (Hard and Lendel, 2012). This includes organic dyes 
like Congo red (Mathis et al., 2004) but also natural compounds such as (-)-
epigallocatechin gallate (EGCG) or curcumin (Ehrnhoefer et al., 2008; Ono et al., 
2004). The polyphenol EGCG, e.g., was shown to efficiently inhibit spontaneous A 
fibrillization by directly binding to the unfolded polypeptides and promoting their 
conversion into off-pathway oligomers (Ehrnhoefer et al., 2008).  
For most anti-amyloid compounds, however, mechanisms of action and exact 
molecular targets remain unclear (Young et al., 2017). It is unknown how they 
engage with aggregation-prone Astructures or whether they affect the activity of 
seeding-competent Aaggregates formed in brains of model organisms and patients. 
Previous investigations indicate that seed-mediated A polymerization is more rapid 
than spontaneous aggregation (Harper and Lansbury, 1997), suggesting that 
inhibition of Aseeding with chemical compounds is more challenging. As a 
therapeutic strategy, however, it might be more promising, because seeding is a 
narrowly defined step in amyloidogenesis. Inhibiting it might halt progression of 
aggregate formation and disease. We hypothesize that only a fraction of the 
previously described amyloid targeting compounds might be active in seed-mediated 
A polymerization reactions in vitro. 
In this study, we first developed a fluorescence polarization (FP)-based assay 
in order to identify chemical compounds that influence A42 polymerization under 
seeded and non-seeded conditions. Systematic compound testing with a small 
 5 
 
focused library of potential amyloid-binding structures revealed the small molecule 
DO1 [4-((4-nitrophenyl)diazenyl)-N-phenylaniline], which most potently delayed both 
seeded and non-seeded A42 aggregation in FP assays. For the screening, 
preformed fibrillar A42 aggregates prepared from synthetic peptides were utilized to 
seed A42 polymerization. Compound effects were also found with A structures 
isolated from brains of AD transgenic mice, demonstrating that DO1 targets 
aggregates that are relevant to disease. Mechanistic studies in cell-free assays 
further substantiated the inhibitory effect of DO1 on seeded A42 polymerization, 
indicating that the compound can disrupt preformed seeding-competent fibrillar 
structures. The potency of DO1 was finally investigated in 5xFAD transgenic mice, 
demonstrating a decrease of A aggregates in brains and an improvement of nesting 
behavior. Strikingly, DO1 treatment also caused a decrease of abnormal 
inflammation-related expression changes in brains of these mice. The implications of 
our results for therapeutic strategies for AD and other amyloid diseases are 
discussed. 
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Results  
Small molecules influence seed-mediated A42polymerization in FP assays  
In previous studies chemical inhibitors of amyloid polymerization have been 
identified using Thioflavin T (ThT)-based aggregation assays (Arosio et al., 2014). 
ThT is a small benzothiazole molecule that changes its emission wavelength upon 
binding to fibrillar -sheet-rich structures, enabling its application as a reporter 
molecule for quantifying the time-dependent formation of A42 fibrils (Arosio et al., 
2014). However, chemical compounds with emission wavelengths that overlap with 
that of aggregate-bound ThT cannot be investigated with ThT assays (Jameson et 
al., 2012). Also, a decrease in ThT fluorescence assumed to arise from inhibiting 
fibrillogenesis may simply be the result of compound binding to the ThT binding site 
on amyloid aggregates (Aitken et al., 2003). To overcome these limitations of the 
state-of-the-art ThT assay, we established a fluorescence polarization (FP)-based 
aggregation assay. The principle of this method is shown in Figures 1A and 1B. In 
this assay, FP is used to study the time-dependent molecular interactions of A42 
peptides by monitoring the changes in the apparent size of interacting fluorescently 
labeled molecules over time. A42aggregation is reflected by an increase in the FP 
signal, which is proportional to a decrease in motility of fluorescently labeled A42 
assemblies as they grow larger through polymerization.  
In proof-of-principle experiments, we first compared whether ThT- and FP-
based amyloid polymerization assays yield similar kinetic profiles. We incubated 
A42 monomers (10 µM) in the presence of FAMA42 (0.05 µM) tracer in 384-well 
plates and quantified the increase of FP over time. Similarly, A42 peptides (10 µM) 
were incubated in the presence of ThT (5 µM) in 384-well plates; fluorescence was 
measured at 440/485 nm. A concentration of 5 µM ThT was necessary to obtain a 
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reproducible signal-to-noise ratio. We found that FP- and ThT-based assays result in 
very similar A42 aggregation profiles (Figure S1A), indicating that they both mirror 
the time-dependent formation of -sheet-rich fibrillar structures from unstructured 
A42 monomers.  
Next, we assessed whether the established FP-based aggregation assay can 
be applied to quantify the seeding activity of preformed -sheet-rich A42 fibrils. We 
incubated 5-FAM-labeled (0.1 M) and unlabeled (10 M) A42monomers in the 
presence and absence of preformed A42 fibrils (seeds) and monitored 
FAMA42/A42 co-polymerization by quantification of FP. We found that in the 
absence of seeds peptides spontaneously co-assemble into high-molecular-weight 
aggregates after a lag phase of ~6 h (Figure 1C, blue curve). Through the addition of 
A42 seeds, however, the lag phase was shortened, indicating that seeding activity 
of synthetic A42 assemblies can be quantified in a concentration-dependent 
manner. Biochemical studies confirmed that the preformed A42 seeds added to FP 
reactions are ThT-reactive, -sheet-rich fibrillar structures (Figures S1B and S1C).  
We utilized the established FP assay to investigate the effects of selected 
small molecules on seed-mediated and spontaneous FAMA42/A42 co-
polymerization. We selected 9 chemical compounds based on the following criteria: 
(1) they are already known to target amyloidogenic, aggregation-prone polypeptides 
or should be related to such structures (Jiang et al., 2013); (2) they should be small 
(< 500 Da) and lipophilic (Lipinski et al., 2001) in order to be orally active and to cross 
the blood-brain barrier (BBB) in mice (Table S1, compounds #1 - #9). Compounds 
were added at substoichiometric concentrations (1 M) to FP reactions (10 M A42 
and 0.1 M FAMA42 tracer) to avoid compound self-aggregation (Feng et al., 2008). 
Under these conditions, only #4 (N,N-dimethyl-4-(phenyldiazenyl)aniline) efficiently 
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delayed both seeded and non-seeded A42polymerization in FP assays (Figure 
S2A). 
To identify compounds that might be more potent than #4, we next tested 6 
structurally related compounds in FP assays (Table S1, compounds #10 - #15). 
Seed-mediated FAMA42/A42 co-polymerization was most strongly delayed by 
compound #15 [4-((4-nitrophenyl)diazenyl)-N-phenylaniline] (Figure 1D), which is 
related to compound #4. Interestingly, #15 was significantly more effective than the 
closely related #14, which lacks the NO2 group (Figures 1D and S2B-S2D), 
indicating that structure-activity relationships are detectable with FP assays. The 
effect of compound #15 on seed-mediated A42polymerization was observed at 
different substoichiometric concentrations with an EC50 value of ~540 nM (Figures 
1E and 1F). Because of its high potency in FP assays, we focused on #15 for all 
further experiments. Compound #15 is an azo dye named Disperse Orange 1 (DO1) 
(David G. Whitten, 1971), which previously has not been described in the context of 
AD. 
 
DO1 directly targets and disassembles preformed fibrillar A42aggregates 
To investigate whether DO1 directly targets seeding-competent 
A42aggregates, we incubated a mixture of preformed fibrillar, -sheet-rich A42 
aggregates for 24 h in the presence and absence of DO1 and subsequently 
separated soluble from insoluble structures by centrifugation. Then, supernatant and 
pellet fractions were analyzed with dot blot assays (DBAs) using the monoclonal anti-
A antibody 352, which specifically recognizes fibrillar assembles in DBAs (Figures 
S3A and S3B). This antibody was raised against preformed fibrillar A42aggregates 
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because the previously reported anti-fibril antibody OC (Kayed et al., 2007) revealed 
immunoreactivity for both A42 monomers and aggregates (Figure S3A). 
Analysis of untreated samples revealed 352-antibody immunoreactivity 
predominantly in the pellet fraction, indicating that larger protofibrillar and fibrillar 
A42aggregates are separated from smaller structures by centrifugation (Figure 
2A). In DO1-treated samples, however, the immunoreactivity in pellet fractions was 
significantly decreased, while it was increased in the supernatant fractions (Figures 
2A and 2B), indicating that the compound converts larger A42assemblies into 
smaller structures. These results were also validated, when supernatant and pellet 
fractions from compound-treated and untreated samples were analyzed with DBAs 
using the monoclonal anti-A antibodies 6E10 and 4G8 (Figures 2A, S3C and S3D), 
which preferentially recognize A42aggregates in DBAs (Figure S3B).  
Next, we applied a native filter retardation assay (FRA) to investigate the size 
of preformed fibrillar A42aggregates in compound-treated and untreated samples. 
With this method, large protein assemblies can be separated from smaller ones 
through filtration (Wanker et al., 1999). Analysis of compound-treated and untreated 
samples revealed that DO1 treatment significantly decreases the immunoreactivity of 
A42 species retained on cellulose acetate filter membranes, when supernatant and 
pellet fractions were analyzed (Figures 2C and 2D), supporting the results with 
DBAs.  
Finally, we analyzed the effect of DO1 on preformed, fibrillar A42aggregates 
by dynamic light scattering (DLS). With this technique, size distribution profiles of 
particles in suspension can be obtained without their separation on gels or 
membranes. DLS studies revealed that the size of A42aggregates in DO1-treated 
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samples was decreased in comparison to untreated samples (Figure 2E), confirming 
the results obtained with DBAs and native FRAs (Figures 2A-2D). 
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The NO2 group in DO1 is critical for dissociation of fibrillar A42aggregates 
To investigate whether the NO2 group in DO1 is necessary for the disruption of 
fibrillar A42aggregates (Figure 2A-2D), we incubated preformed assemblies with 
DO1 or the related compound #14, lacking the NO2 group (Figure 1D), for 24 h at 
37 °C. Then, supernatant and pellet fractions were produced by centrifugation and 
analyzed with blue native gels and immunoblotting (Figure 2F). We detected both 
low-molecular-weight (LMWAs, ~60-200 kDa) and high-molecular-weight 
A42assemblies (HMWA, material retained in the gel pockets) in the supernatant 
fractions of untreated samples, while in the pellet fractions exclusively HMWAs were 
observed. In DO1 treated samples, however, the abundance of HMWAs in the pellet 
fractions was decreased in comparison to untreated controls, while the abundance of 
LMWAs in the supernatant fractions was increased (Figure 2F). This confirms our 
initial observations that DO1 disrupts preformed fibrillar A42 aggregates and 
promotes the formation of smaller structures. Strikingly, such an effect was not 
observed when the samples were incubated with the related compound #14 that 
lacks the NO2 group (Figures 1D and 2F). 
 
DO1 treatment kinetically traps small, non-toxic A42 oligomers 
 Our studies indicate that substoichiometric concentrations of DO1 can slow 
down A42 fibrillogenesis (Figures 1E and S2B), suggesting that compound 
treatment may increase the abundance of small, proteotoxic A42 oligomers in 
aggregation reactions. To address this question, we incubated monomers (0.05 M 
FAMA42 and 10 M A42) in the absence and presence of DO1 (1 and 5 M) for 16 
h at 37 °C. Then, samples were systematically analyzed by AFM. We observed a 
higher number of small spherical A42 oligomers with a height of ~1 nm in DO1 
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treated than in untreated samples (Figure 3A and 3B), indicating that the compound 
kinetically traps small prefibrillar A42 structures. This was also confirmed when 
seeded compound-treated and untreated FAMA42/A42 co-polymerization reactions 
were analyzed (Figures S4A and S4B) or when spontaneous reactions were 
investigated by blue native PAGE and immunoblotting. In comparison to untreated 
samples, we observed an increase of LMWAs with a size of ~200-500 kDa in DO1-
treated samples (Figure 3C), supporting the results obtained by AFM (Figures 3A 
and 3B).  
 Finally, we carried out 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) reduction assays (Berridge et al., 2005) with PC12 cells to assess the 
toxicity of DO1 treated and untreated FAMA42/A42 co-aggregation reactions. In 
agreement with previous studies (Ehrnhoefer et al., 2008), formation of -sheet-rich 
fibrillar aggregates (untreated samples) caused a pronounced inhibition of MTT 
reduction (~40%), indicative of cellular toxicity. However, inhibition of MTT reduction 
was significantly decreased with DO1 treated samples (Figure 3D), indicating that 
the compound-stabilized structures observed by AFM (Figure 3A) are less toxic than 
A42 fibrils in cell-based assays. 
 
DO1 decreases seeding activity of A aggregates prepared from AD mouse 
brains 
Previous studies suggest that seeding-competent A aggregates in brains of 
AD patients and transgenic mice are responsible for disease progression and 
development (Jucker and Walker, 2013). We therefore addressed the question of 
whether DO1 can influence the seeding activity of potentially disease-relevant A 
aggregates prepared from brains of AD transgenic mice (Heilbronner et al., 2013).  
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To prepare such structures, brain extracts from 22-month-old APPPS1 mice 
were first immunoprecipitated with beads using the monoclonal anti-A antibodies 
6E10 and 352 (Figure 3E). The precipitated material was then released from the 
beads by sonication and analyzed by SDS-PAGE and immunoblotting. We found that 
both anti-A antibodies precipitated high molecular weight A aggregates (retained in 
the gel pockets) from mouse brain extracts (Figure 3E). In contrast, such structures 
were not enriched from brain extracts with the control antibody IgG1. 
Next, the prepared fractions were treated with DO1 and added as “seeds” to 
FP-based aggregation assays. We observed a pronounced shortening of the lag 
phase when 352 or 6E10 immunoprecipitates were added to FP assays (Figures 3F 
and S4C). In contrast, no such an effect was obtained with IgG1 immunoprecipitates 
(control), indicating that only antibody-enriched A aggregates possess seeding 
activity. Finally, we found that DO1 treatment in a concentration-dependent manner 
extends the lag phase of A aggregation in FP assays (Figures 3F and S4C), 
indicating that the compound directly targets disease-relevant A structures and 
reduces their seeding activity. 
 
DO1 decreases the formation of A aggregates in brains of 5xFAD mice  
Based on our seeding studies with A aggregates from mouse brains (Figure 
3F), we hypothesized that DO1 might also show activity in vivo. To address this 
question, we first assessed whether DO1 enters the brain. The compound was 
administered orally and the concentration was measured in crude brain extracts after 
acetonitrile precipitation by RP-LC-MS. We readily detected DO1 in mouse brain 
homogenates (Figure S5A), indicating that the compound crosses the blood-brain 
barrier. Next, we performed a histopathological examination of DO1-treated wild-type 
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mice to assess potential toxic effects of the chemical compound. We treated groups 
of mice by oral gavage with 2, 30 and 150 mg/kg DO1 once daily for 7 days. Mice 
were observed regularly; no overt toxic signs were detectable. After 7 days, mice 
were sacrificed and organs such as brain, heart, liver, lung, stomach, intestine, 
spleen and kidney were evaluated histopathologically. No macroscopic and 
microscopic changes related to DO1 treatment were detected, indicating that mice 
can be treated with this compound without major adverse effects.  
We administered DO1 orally for 8 months to 6 week-old 5xFAD (Oakley et al., 
2006) mice to study its effects on A aggregation in vivo. Previous investigations 
indicate that the first amyloid plaques are detectable in brains of 5xFAD mice after ~2 
months and increase in their abundance over time (Oakley et al., 2006). We 
administered the compound via compound-fortified food pellets (0.625 g/kg feed) and 
analyzed the impact of DO1 on Aaggregation in hippocampal brain regions at 9.5 
months of age using immunohistochemical methods. For the detection of amyloid 
structures, the anti-A antibodies 352 and 6E10 were applied. We observed that the 
numbers and sizes of antibody-reactive Aplaques were significantly decreased in 
compound-treated animals in comparison to untreated animals (p < 0.001; Figures 
4A-4C). Interestingly, no significant compound effect was detected when A plaques 
were stained with the dye Congo red (CR) (Figure 4D), which predominantly detects 
dense core regions in fibrillar Aplaques (Frid et al., 2007). This indicates that DO1 
treatment diminishes the growth of the more diffuse outer spheres of Aplaques, 
which contain small fibrillar Aoligomers (Koffie et al., 2009), while it cannot alter the 
size of the congophilic dense core regions in amyloid plaques. A very similar result 
was obtained when cortical brain regions of DO1 treated and non-treated AD 
transgenic mice were analyzed (Figures S5B-S5E). 
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To further explore the effect of DO1 on plaque formation, we performed co-
staining experiments with the dye Thioflavin S (ThS) and the antibody 352. Similar to 
CR, ThS predominantly detects dense core regions in amyloid plaques (McLellan et 
al., 2003). In comparison, the 352 antibody preferentially detected small fibrillar A 
aggregates in DBAs (Figure S3B), suggesting that it might stain the outer spheres of 
amyloid plaques, which contain Aoligomers (Koffie et al., 2009). We found that the 
sizes of 352-reactive Aplaques were significantly decreased in compound-treated 
animals in comparison to untreated ones (Figures 4E and 4F). In contrast, no 
significant compound effect was observed when ThS-positive dense core plaque 
regions were analyzed (Figure 4G).  
Next, we assessed the abundance of A aggregates in compound-treated and 
untreated AD mouse brains with a native FRA (Wanker et al., 1999) using the anti-A 
antibody 352. We observed a significant decrease of 352-reactive A aggregates in 
compound-treated samples compared to untreated controls (Figures S5F and S5G), 
supporting our results obtained with immunohistological methods (Figures 4A and 
S5B). 
Finally, we investigated whether DO1 treatment alters the abundance of the 
marker protein GFAP (glial fibrillary acidic protein) in AD brains. Previous studies 
indicate that the formation of Aplaques in 5xFAD brains is associated with an 
increase of GFAP (Oakley et al., 2006), suggesting that a decrease in A aggregates 
in DO1 treated mice might be accompanied by a decrease of this disease marker 
protein. Analysis of mouse brain extracts with ELISAs revealed significantly lower 
GFAP levels in DO1-treated AD animals than in untreated controls (Figure S5H), 
indicating that compound treatment (Figures 4A-4C) decreases the abundance of 
relevant marker proteins in AD brains. 
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DO1 treatment improves nesting behaviour in 5xFAD transgenic mice  
To elucidate whether DO1 treatment influences behavioural deficits in AD 
transgenic mice, we assessed the ability of compound-treated and untreated animals 
to build nests, a natural social behaviour of mice requiring spatial memory and 
hippocampal neuronal functions that are affected in AD (Lin et al., 2007; Mufson et 
al., 2015). We treated 6 week-old female 5xFAD and wild-type control mice for 8 
months with DO1 and subsequently assessed their nest-building ability using a 
standardized protocol (Deacon, 2006). At an age of 9.5 months, the AD transgenic 
mice exhibited a significant impairment in nesting behaviour compared to age-
matched wild-type controls (Figure 5A). This behaviour, however, was significantly 
improved in DO1-treated AD transgenic mice. In order to validate the DO1 effect on 
nesting behaviour, we repeated the drug trial with 5xFAD transgenic mice in an 
independent research laboratory, this time using male mice to assess efficacy. In this 
validation study, 6-week-old male 5xFAD and control mice were treated with DO1 for 
6 months. We found that DO1 treatment again significantly improved the nest 
building performance of AD transgenic mice (Figure 5B), essentially confirming the 
results from the initial drug trial with female mice.  
 
DO1 reduces transcriptional changes related to neuroinflammation in brains of 
5xFAD mice 
 Previous investigations indicate that the time-dependent deposition of 
Aaggregates in brains of 5xFAD transgenic mice correlates with global changes in 
gene expression (Landel et al., 2014). This includes increased expression of multiple 
transcripts encoding proteins involved in inflammation (Landel et al., 2014), 
suggesting that DO1 treatment might influence these expression changes in AD 
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brains. To test this hypothesis, we analyzed gene expression in brains of DO1 
treated and untreated 5xFAD and control mice using a microarray technology (data 
accessible at NCBI GEO database (Edgar et al., 2002), accession GSE119756). 
DO1 was administered orally for 8 months to 6-week-old mice. In total, transcripts of 
4 groups of treated and untreated mice (TG+DO1, TG, WT+DO1 and WT) were 
systematically investigated. 
 Principal component analysis (PCA) of the gene expression data showed that 
the samples clustered into four broad groups correlating with disease and treatment 
status. PCA revealed a clear separation of data obtained from AD and non-AD brains 
(Figure 6A), confirming previous observations (Landel et al., 2014). Furthermore, we 
observed that the compound DO1 alters the transcriptional profiles in brains of 
5xFAD and wild-type control mice (Figure 6A). 
 We first compared the gene expression in brains of untreated 5xFAD and 
control mice. We found that 290 genes are differentially expressed in AD and non-
disease (TGvsWT) brains, of which 257 genes (88.6%) were upregulated in AD 
brains, while 33 (11.4%) were downregulated (Figure 6B). We next investigated 
whether DO1 treatment influences the dysregulation in gene transcription in brains of 
5xFAD transgenic mice. We observed 208 genes differentially expressed between 
DO1-treated AD and DO1-treated wild-type (WT) control (TG*vsWT*) animals, of 
which 204 (98.1%) and 4 (1.9%) genes were up- and downregulated, respectively 
(Figure 6B). This indicates that compound treatment decreases the number of 
significantly dysregulated genes in AD brains. In comparison, a higher number of 
differentially expressed genes was obtained when the data of DO1-treated AD and 
untreated WT control animals (TG*vsWT) were compared. In this case, 625 
significantly dysregulated genes were obtained, of which 355 (56.8%) and 270 
(43.2%) were up- and down-regulated, respectively. This supports the results of PCA 
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(Figure 6A), indicating that compound treatment leads to expression changes in both 
transgenic and WT brains. To assess the impact of DO1 on brains of WT control 
mice, we finally compared the gene expression data of compound-treated and 
untreated WT mice (WT*vsWT). In this case, we detected 203 significant expression 
changes (Figure 6B); 130 genes (64%) were up-regulated, 73 genes (36%) were 
down-regulated, confirming our assumption that chronic DO1 treatment induces 
transcriptional changes in WT mouse brains. 
We used ingenuity pathway analysis (IPA, Kramer et al., 2014), to identify the 
pathways that are potentially altered in brains of DO1-treated and untreated 
transgenic and WT mice. Analysis of TGvsWT, TG*vsWT* and TG*vsWT datasets 
revealed gene expression changes predominantly in neuroinflammation signaling 
pathways (Figures S6A-S6C), confirming previous reports (Landel et al., 2014). The 
analysis of the WT*vsWT dataset, however, revealed significant expression changes 
in the cholesterol biosynthesis pathway (Figure S6D), suggesting that DO1 alters 
pathways in WT brains that are distinct from TG animals. Previous investigations 
revealed that in 5xFAD mice many well-known markers of microglia cells and 
astrocytes such as TREM-2 (triggering receptor expressed on myeloid cells 2) or 
GFAP are upregulated in comparison to WT controls (Landel et al., 2014). We 
therefore inspected the top 20 upregulated genes in the TGvsWT dataset for genes 
that are typically activated in AD brains. We found a large number of well-known 
inflammation and immune markers such as Cst7 (Cystatin F) or TREM-2 (Figure 
6C). Furthermore, an upregulation of the astrocyte marker GFAP was observed, 
confirming our results obtained with ELISAs (Figure S5H). Together these results 
support our hypothesis that the deposition of A aggregates leads to activation of 
microglia and astrocytes in brains of 5xFAD mice.  
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We finally assessed whether compound treatment leads to quantitative 
changes in the transcript levels of genes that are upregulated both in the TGvsWT 
and TG*vsWT* datasets. We identified 186 shared genes in these datasets (Figure 
6D). Importantly, we found that DO1 treatment significantly counteracts upregulation 
of genes in 5xFAD brains (Figure 6E). The results are shown for the 20 top 
upregulated genes in Figure 6C. Very similar results were obtained when the 
expression of upregulated genes in the TG*vsWT dataset was analyzed (Figures 6F-
6H).  
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Discussion 
Here, we describe a drug discovery strategy to identify small molecules that 
decrease the seeding activity of fibrillar, -sheet-rich A structures in vitro and in 
vivo. This strategy involves: (1) the identification of compounds that reduce the 
seeding activity of preformed, fibrillar A42 aggregates with a FP-based amyloid 
polymerization assay, (2) the investigation of compound effects on preformed A42 
seeds with biochemical and biophysical methods, (3) the analysis of compound 
effects on potentially disease-relevant A seeds prepared from brains of AD 
transgenic mice and (4) the investigation of selected compounds in the progressive, 
well-described 5xFAD transgenic AD mouse model (Oakley et al., 2006). In a proof-
of-concept study, we identified the aromatic small molecule DO1 [4-((4-
nitrophenyl)diazenyl)-N-phenylaniline] that potently decreases the activity of synthetic 
and mouse-derived A seeds in cell-free FP assays (Figures 1E and 1F). Also, it is 
active in vivo in the brains of transgenic 5xFAD mice. This model bears five 
mutations linked to familial forms of AD and recapitulates the main features of the 
disease in a few months (Oakley et al., 2006). Treatment with DO1 not only 
decreased fibrillar A aggregates (Figures 4A and 4E) but also neuroinflammatory 
gene expression changes (Figures 6E-6H) associated with amyloid deposition and 
improved a behavioural phenotype, i.e. nesting (Figures 5A and 5B). 
In contrast to previously reported A aggregation modulators such as 
tramiprosate (Gervais et al., 2007), RS-0406 (Nakagami et al., 2002), RO90-7501 
(Bohrmann et al., 2000) or scyllo-inositol (McLaurin et al., 2002), DO1 can decrease 
the seeding activity of preformed A42 fibrils at substoichiometric concentrations in 
FP assays (Figure S2). This suggests that the molecular mechanism by which DO1 
perturbs A42 aggregation is distinct from previously described small molecules. We 
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hypothesize that DO1 directly targets and disrupts seeding-competent, fibrillar A42 
structures in aggregation reactions and that this specific activity is responsible for the 
observed extension of the lag phase and the delay of A42 fibril growth (Figure 1E). 
It is important to note that both fibrillar and pre-fibrillar aggregates are formed during 
the lag phase in A42 polymerization reactions (Lee et al., 2011); both may be 
targeted by DO1. More detailed investigations using biochemical, structural and 
biophysical methods are necessary to elucidate the precise mechanism of action of 
DO1 in seeded and non-seeded A42 polymerization reactions. These studies 
should also involve the focused analysis of the impact of the compound on primary 
and secondary nucleation as well as on fibril elongation, as all these three 
microscopic processes are operative during the lag phase in A42 amyloid 
aggregation (Arosio et al., 2015).  
DO1 treatment significantly decreases the size and the abundance of A 
plaques in brains of 5xFAD transgenic mice (Figures 4A-C). Focused histological 
studies revealed that especially the diffuse outer spheres of amyloid plaques were 
significantly reduced, while the dense core regions were not influenced (Figures 4D 
and 4G). Previous studies indicate that synaptic transmission is severely impaired in 
brains of 5xFAD mice and that this deficiency correlates with the high abundance of 
diffuse amyloid plaques (Crouzin et al., 2013), suggesting that these structures 
contribute to the development of AD-related symptoms. Small, fibrillar Aoligomers 
were shown to be enriched in the outer spheres of amyloid plaques (Koffie et al., 
2009). We hypothesize that DO1 decreases the abundance of diffuse amyloid 
plaques because it directly targets self-propagating, fibrillar A aggregates and 
promotes their dissociation and degradation. This activity may also be responsible for 
the compound’s effect on immune hyperactivity, caused by Aplaque-associated 
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microglia (Landel et al., 2014). Thus, we suggest a similar mechanism of action of 
DO1 both in vitro and in vivo.  
Our studies indicate that the Aaggregate-targeting compound DO1 has 
beneficial effects on the disease process in 5xFAD transgenic mice. This is in 
agreement with previously reported observations: Inhibiting seed-mediated A 
aggregation with the FDA-approved drugs mitoxantrone and bithonol reduced 
synapse loss and neuronal damage in APP transgenic mice (Eleuteri et al., 2015). 
Similarly, cognitive deficits were decreased when transgenic APP/PS1 mice were 
treated with the small molecule EPPS, which can disaggregate higher-molecular-
weight A structures in cell-free assays (Kim et al., 2015). Thus, our observations 
with DO1 are not without precedent and provide compelling support for the amyloid 
hypothesis. 
 
Significance 
Several small molecules targeting the aggregation process of the A peptide 
have been reported. How they act at the molecular level and whether they influence 
seed-mediated A polymerization, a process which happens faster than spontaneous 
A aggregation and has recently emerged as the potential driver of disease, is 
largely unknown. We have developed an FP-based A polymerization assay and 
could show that it identifies potent modulators of both seeded and spontaneous A 
aggregation. Using it, we have discovered a compound, DO1, that targets preformed 
A aggregates and efficiently reduces their seeding activity at substoichiometric 
concentrations. DO1 is also active in vivo. It improves plaque pathology and 
behaviour and reduces immune hyperactivity of A plaque-associated microglia in 
transgenic Alzheimer mice. Our evidence supports the hypothesis that seeding-
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competent, fibrillar amyloid aggregates are disease-relevant structures (Tipping et 
al., 2015) and that targeting them with small molecules is a promising therapeutic 
strategy. We regard DO1 as a tool compound investigated in a proof-of-concept 
study. We intend to stimulate further research and development to find improved, 
structurally related molecules that bring about a therapeutic effect by targeting 
seeding-competent amyloid aggregates and their propagation. We do not wish to 
suggest in any way that DO1 can already be used for medication. On the contrary, 
comprehensive pharmacological and toxicological assessment, i.e. hit-to-lead 
development, would be required prior to a potential evaluation in a clinical trial.  
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Figure legends 
Figure 1 (see also Figures S1 and S2). Establishment of a fluorescence 
polarization-based A42 aggregation assay.  
(A) Assay principle. Fluorescently labeled A42 peptides (tracer) are incorporated 
into growing A42 aggregates during the aggregation process. 1) Initially, reactions 
are dominated by small structures, rotating rapidly in solution. 2) As polymerization 
proceeds, larger aggregates rotating more slowly are formed.  
(B) Time-dependent reduction of tracer mobility in the course of aggregation results 
in an increase of the polarization signal (milli-polarization, mP). 1) Highly mobile, non-
incorporated tracer molecules emit light in various planes of oscillation. 2) 
Incorporated tracer molecules emit fluorescent light predominantly in the excitation 
plane.  
(C) Concentration-dependent seeding effect of preformed fibrillar aggregates (FAs; 5 
to 200 nM monomer equivalent) in FP assays. Average values were derived from 
quadruplicates of each sample. 
(D) Structural formula of compounds #14 and #15/ DO1.  
(E) Concentration-dependent effect of DO1 (0.05 to 2.5 µM) on seed-mediated 
FAMA42 (0.1 M)/A42 (10 M) co-aggregation in FP assays. Average values were 
derived from triplicates of each sample.  
(F) Calculation of the EC50 value for DO1 from aggregation profiles shown in E at 
5.5 h. 
Data in C, E and F are represented as mean ± SD. 
 
Figure 2 (see also Figure S3). Effects of DO1 on fibrillar A42 assemblies.  
 32 
 
(A) Dot-blot assays (DBAs) of DO1-treated and untreated (control, ctrl) A42 fibrillar 
aggregates (FAs). After DO1 treatment (24 h, 37 °C) A42 FAs were centrifuged; 
supernatant (S) and pellet (P) fractions were analyzed by DBAs using the antibodies 
352, 4G8 and 6E10. Quadruplicates per sample were analyzed. A representative 
experiment is shown.  
(B) Box plot of relative quantification of 352 antibody immunoreactivity shown in A. 
Two-way analysis of ANOVA showed a significant DO1 treatment effect (F2,18 = 
63.32, p = 7.16e-09) and position (antibody reactivity in pellet versus supernatant) 
effect (F1,18 = 13.20, p = 0.0019). There was also a significant interaction between 
treatment and position effects (F2,18 = 152.86, p = 5.08e-12), indicating that DO1 
converts larger fibrillar A42 aggregates into smaller structures.  
(C) Analysis of supernatant and pellet fractions as in A by filter retardation assay 
(FRA). Prior to the preparation of supernatant and pellet fractions, preformed A42 
FAs (equivalent to a monomer concentration of 1 µM) were incubated with a 5-fold 
molar excess of DO1 for 24 h at 37 °C. A42 species retained on filter membranes 
were detected with 6E10.  
(D) Box plot quantification of triplicate samples from native FRAs shown in C. 
Treatment with DO1 significantly decreased the 6E10 immunoreactivity both in the 
supernatant (p = 9.892e-06) and the pellet (p = 4.823e-05) fractions. p-values were 
calculated with unpaired two tailed t-test.  
(E) Analysis of DO1-treated and untreated pellet fractions by dynamic light scattering 
(DLS). The size distribution of A42 aggregate species is shown.  
(F) Analysis of supernatant (S) and pellet (P) fractions of DO1- or #14-treated 
samples by native PAGE and Western blotting. For immunoblotting, the anti-A 
antibody 4G8 was used. 
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Figure 3 (see also Figure S4). DO1 traps small A42 oligomers and reduces the 
seeding activity of A aggregates prepared from AD mouse brains.  
(A) AFM analysis of aggregate species derived from compound treated and 
untreated FAMA42 (0.05 µM)/Aβ42 (10 µM) co-aggregation reactions after incubation 
for 18 h. Samples were analyzed using the AFM probe PPP-NCHAuD. Color 
gradient: 0-10 nm height.  
(B) Number of oligomers were counted in three different areas (0.5 x 0.5 µm each) of 
respective AFM pictures in A. *** p<0.001, * p<0.05, one-way ANOVA. Data show 
mean ± SEM. 
(C) Analysis of FAMAβ42/Aβ42 co-assemblies shown in A after 18 h by native PAGE 
and immunoblotting using the anti-Aβ antibody 6E10.  
(D) MTT assay. Effects of DO1 treated and untreated Aβ42 aggregation reactions 
after 18 h (shown in A) on MTT reduction in PC12 cells. As a control, cells were 
treated with 0.05 µM and 0.25 µM DO1 alone, which is equivalent to the amount of 
compound added to cells in FAMAβ42/Aβ42 aggregation reactions. Values represent 
percentage of buffer control. Statistical significance was assessed by one-way 
ANOVA followed by Dunnett's multiple comparison post hoc test. **, p≤0.01.  
(E) Analysis of immunoprecipitates prepared from APPPS1 mouse brain extracts by 
SDS-PAGE and immunoblotting. IP: immunoprecipitation; A-specific antibodies: 352 
and 6E10; control antibody: IgG1. Precipitated A aggregates are indicated with 
asterisks. Input: 10% brain homogenate; FT, flow-through; Wash: wash fractions. 
Immunoblot: 6E10 antibody; HC, heavy chain; LC, light chain.  
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(F) Effects of different concentrations of DO1 on seeding activity of A species 
immunoprecipitated from APPPS1 mouse brain homogenates (6E10-IP). Average 
values derived from quadruplicates of each sample in the experiment. 
Data in D and F are represented as mean ± SD.  
 
Figure 4 (see also Figure S5). Effects of DO1 on amyloid- plaques in 5xFAD 
transgenic mice.  
(A) Immunohistochemical detection of A plaques in the hippocampus of 5xFAD 
female mice treated for 8 months with 0.652 g DO1 per kg of mouse chow. Top and 
middle rows, 3,3'-diaminobenzidine (DAB) staining of A plaques with 352 and 6E10 
antibodies. Bottom row, Congo red staining of A plaques. Scale bar is equal to 50 
m and applies to all images. 
(B-C) Quantification of 352 (B) and 6E10 (C) immunoreactivities; ***p < 0.001 versus 
control, one-way ANOVA, n = 4-5 mice per group.  
(D) Quantification of Congo red stained dense core plaques in hippocampal regions.  
(E) Analysis of hippocampal brain sections of female DO1-treated and untreated 
5xFAD transgenic mice by immunofluorescence microscopy. Top, 352-reactive 
regions. Middle, Thioflavin S (ThS) staining of dense core regions. Bottom, 3-
dimensional merge of ThS and 352 antibody stains. The scale bar is equal to 200 
m.  
(F-G) Quantification of 352- (F) and ThS-stained (G) A plaques in mouse brains 
(***p < 0.001, one-way ANOVA, n = 4 mice per group).  
Data in B - D, F and G are represented as mean ± SEM. 
 
 35 
 
Figure 5 (see also Figure S5). Effects of DO1 on nesting behavior of 5xFAD 
transgenic mice.  
(A) Nest building activity of 9.5 month-old female wild-type (Wt) and 5xFAD 
transgenic (Tg) mice treated with DO1. DO1-treated transgenic mice were compared 
to untreated transgenic control mice (genotype Chi-Square = 25.797, df = 3, p-value 
= 1.052e-5, Kruskal-Wallis Test; p-value = 0.0003013 [treated versus control 5xFAD], 
pairwise exact Wilcoxon Test, n = 14-19).  
(B) Nest building activity of male wild-type (Wt) and 5xFAD transgenic (Tg) mice 
treated with DO1. The compound significantly improved the nestlet quality score of 
7.5 month-old male AD mice in an independent experiment (Chi-squared = 8.9374, df 
= 3, p-value = 0.03013, Kruskal-Wallis Test; p-value = 0.01204 [treated versus 
control 5xFAD], pairwise exact Wilcoxon Test, n = 15 -18). 
 
Figure 6 (see also Figure S6). Differential gene expression analysis of DO1 
treated and untreated 5xFAD and control mice.  
(A) Principal component analysis of untreated and DO1 treated wildtype (WT, WT*) 
and transgenic mice (TG, TG*) based on log2 normalized gene expression values.  
(B) Overview of significantly (p < 0.05) up- (red) and down-regulated (blue) genes in 
untreated und treated groups of WT and TG mice. The statistical significance was 
assessed with an unpaired, two-tailed t-test (***p < 0.0001).  
(C) Top 20 up-regulated genes from TGvsWT and TG*vsWT* gene expression 
datasets.  
(D) Intersection of upregulated genes in TGvsWT and TG*vsWT* gene expression 
datasets. 
(E) Comparison of the log2 (fold change) of the intersection of upregulated genes in 
TGvsWT and TG*vsWT* datasets. Boxplots extend from the lower to the upper 
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quartiles, with the internal lines referring to the median values. Statistical significance 
was assessed by a paired, two-tailed t-test (***p < 0.0001). 
(F) Top 20 up-regulated genes from TGvsWT and TG*vsWT gene expression 
datasets. 
(G) Intersection of upregulated genes in TGvsWT and TG*vsWT datasets. 
(H) Comparison of the log2 (fold change) of the intersection of upregulated genes in 
TGvsWT and TG*vsWT datasets. Boxplots extend from the lower to the upper 
quartiles, with the internal lines referring to the median values. Statistical significance 
was assessed by a paired, two-tailed t-test (***p < 0.0001). 
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Contact for Reagent and Resource Sharing 
Further information and requests for resources and reagents should be directed to 
and will be fulfilled by the lead contact, E. E. Wanker (ewanker@mdc-berlin.de). 
 
Experimental Models and Subject Details 
Mouse models and breeding. Hemizygous male 5xFAD mice B6SJL-
Tg(APPSwFlLon,PSEN1*M146L*L286V 6799Vas/jax (Oakley et al., 2006) on a 
50:50 C57BL/6J x SJL/J (BL6SJL) background were mated to female BL6SJLF1/J 
mice. Resulting offspring were weaned at approximately three weeks of age; 
genotyping for the APP transgene and the blind mutation was performed by PCR 
with tissue biopsies (Oakley et al., 2006). 5xFAD transgenic mice overexpress two 
human AD-related proteins: the mutant human APP (695) protein with the Swedish 
(K670N), Florida (I716V) and the London (V717I) mutations and the human PS1 
protein with the mutations M146L and L286V. Treatment of mice with DO1 started at 
an age of six weeks. Animal care was in accordance with the Directive 2010/63/EU of 
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the European Parliament and the Council on the protection of animals used for 
scientific purposes. All experimental procedures were approved by the local animal 
welfare authority in Berlin, Germany under license number TVV G0077/07. Mice 
were group-housed (5/cage) with wood shavings. Environmental enrichment was 
achieved by providing each cage with a play tunnel, shredded paper and a wood 
block. Food and water were provided ad libitum. All mice in the DO1 group received 
DO1-supplemented pelleted mouse chow at a concentration of 0.652 g/kg food.  
 
Nest building. Approximately one hour before the dark phase (light-dark phase 12 
h:12 h), each mouse was given 3 g of nestlet made of pressed cotton (Lillico, Surrey, 
UK). The nests were assessed the next morning as described before (Deacon, 
2006). The scoring scale for nestlet usage was: 1, >90% intact; 2, 50-90% intact; 3, 
10-50% intact; 4, 0-10% intact, flat nest; 5, 0-10% intact, crater-shaped nest. In 
another evaluation, the untorn nesting material was weighed after brushing off loose 
material and bedding wood chips and subtracted from the initial weight to obtain 
nestlet usage in percent. 
 
Brain tissue processing. Animals were transcardially perfused with 25 ml 0.9% 
saline under deep anesthesia using ketamin (65 mg/kg), xylazin (13 mg/kg) and 
acepromazin (2 mg/kg) (Arras et al., 2001). Mice were sacrificed by cervical 
dislocation; brains were removed and divided into hemispheres. The left hemisphere 
was used for biochemistry while the right hemisphere was used for 
immunohistochemistry. The right hemisphere was post-fixed by immersion in 4% 
PFA (pH 7.2-7.4) overnight. The brains were cryoprotected by transferring them into 
a solution of 30% sucrose in phosphate buffer, pH 7.4 supplemented with 0.1% 
sodium azide and stored at 4 °C for 48 hours. Following cryoprotection, the brains 
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were frozen in isopentane and stored at -80 °C until use. Hemibrains were sectioned 
coronally (+2.25 mm to -3.5 mm bregma) using a cryostat (Leica Biosystems, Eisfeld, 
Germany). 25 μm thick sections were collected (approximately 27 sections per brain) 
and stored in cryoprotectant antifreeze solution (30% ethylene glycol and 30% 
glycerol in 0.2 M phosphate buffer, pH 7.2) at -20 °C for further processing.  
 
Method Details 
Aβ42 peptide preparation. Synthetic amyloid-β (1-42) peptide (A42) produced by 
the laboratory of Dr. Volkmar-Engert (Institute for Medical Immunology, Charité, 
Berlin, Germany) was dissolved in 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) at a 
concentration of 5 mg/ml. The solution was vortexed and incubated for 4 h at 20 °C. 
Every hour, samples were sonicated for 10 min in a sonicator bath. Incubation of the 
A42 peptide in HFIP was continued for 16 h at 20 °C. Finally, sonicated material 
(30 min) was aliquoted and lyophilized. Monomeric A42 solutions for Thioflavin T 
(ThT) binding assays were prepared by dissolving the lyophilized HFIP-treated 
peptide at a concentration of 200 µM in 10 mM NaOH, followed by 1 min vortexing 
and 5 min sonication in a sonicator bath. For preparation of fibrillar A42 aggregates 
(FAs) lyophilized HFIP-treated A42 peptide was thawed on ice and dissolved at a 
concentration of 10 mg/ml in 100 mM NaOH. After 1 min vortexing and 5 min 
sonication in a sonicator bath, low salt buffer (LSB: 1.9 mM KH2PO4, 8.1 mM 
K2HPO4, 10 mM NaCl, pH 7.4) was added yielding an A42 concentration of 200 µM. 
After 6 h incubation at 37 °C with 300 rpm shaking, the A42 solution was aliquoted 
and stored at -80 °C until use. The morphology and stability of FAs was analyzed by 
atomic force microscopy, native gels, dot blots and ThT binding assays. For 
fluorescence polarization (FP) assays, Aβ42 peptide was purchased from Bachem 
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(Bubendorf, Switzerland, #H-1368). Peptide was dissolved in 1,1,1,3,3,3-Hexafluoro-
2-propanol (HFIP) to a concentration of 5 mg/ml, vortexed for 1 min and sonicated for 
10 min at 4 °C in a sonicator bath. Then, the solution was incubated for 3 h at 22 °C, 
with 1 min vortexing and 1 min sonication every hour. After incubation for further 67 h 
at 22 °C, samples were aliquoted and lyophilized (RVC 2-25 CDplus, Christ, 
Osterode am Harz, Germany). Monomeric A42 solutions were prepared from 
lyophilized peptide aliquots by dissolving them in 10 mM NaOH to yield a final A42 
concentration of 200 µM followed by 1 min vortexing and 5 min sonication. To start 
aggregation reactions for FP assays 200 µM monomeric A42 peptide was diluted in 
LSB to yield a concentration of 10 µM. 
 
Fluorescence polarization-based aggregation assay.  
5-Carboxyfluorescein labeled β-amyloid (1-42) peptide (5-FAM; Anaspec, Fremont, 
CA, USA) was dissolved in 1 mM NaOH to 50 μM and stored as a stock solution at -
20 °C. 0.1 μM of this tracer together with 10 μM Aβ42 monomer in LSB were 
combined with 40 nM (monomer equivalent) Aβ42 FAs (seeds) and test compounds 
(1 µM). The aggregation mixtures were replenished with LSB to a total volume of 
40 µl. The fluorescence polarization measurements were carried out every 15 min at 
37 °C for a minimum of 12h in a plate-reader (Infinite M1000/ Infinite M1000 PRO, 
Tecan, Männedorf, Switzerland) at an excitation wavelength of 470 ± 5 nm and an 
emission wavelength of 528 ± 20 nm in 384-well plates with 5 sec shaking before 
each read. Values are means of five technical replicates. Polarization values are 
expressed as dimensionless milli-polarization (mP) values, calculated by the plate-
reader software i-control (Tecan, Männedorf, Switzerland).  
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Antibodies. To generate a monoclonal antibody that preferentially recognizes A42 
FAs, the prepared amyloid species were injected into mice and hybridomas were 
generated by a proprietary immunization protocol of Synaptic Systems Göttingen 
(see also https://www.sysy.com/services/index.php). Three 8-10 week-old BALB/c 
female mice were subcutaneously immunized with A42 FAs over a period of 17 
days. Cells from the knee lymph nodes were fused with the mouse myeloma cell line 
P3X63Ag8.653 (ATCC CRL-1580). The clones used in this study were re-cloned two 
times by limiting dilution and the immunoglobulin subclass was determined.  
Antibodies secreted by the hybridomas were screened for their reactivity against the 
immunogen using ELISA. Positive antibodies were retested with ELISA against A42 
FAs and monomers. Hybridomas producing antibodies with preference for A42 FAs 
were subcloned to monoclonality and further analyzed by histology and Western 
blotting. One of the antibodies showing specificity for A42 FAs was the antibody 
352. Commercially available antibodies applied in this study are: anti--amyloid 1-16 
antibody (clone 6E10, Biolegend, San Diego, CA, USA); anti--amyloid 17-24 
antibody (clone 4G8, Biolegend, San Diego, CA, USA); anti-amyloid fibrils OC 
antibody (Merck Millipore, Darmstadt, Germany); anti-mouse IgG1 isotype control 
(ThermoFisher Scientific, Waltham, MA, USA); anti-mouse IgG, peroxidase 
conjugated for immunoblots (Sigma-Aldrich, Taufkirchen, Germany); mouse 
monoclonal GFAP antibody and rabbit polyclonal GFAP antibody (Synaptic Systems, 
Göttingen, Germany); goat anti-mouse IgG and peroxidase AffiniPure goat anti-rabbit 
IgG for ELISA (Jackson Immuno Research Laboratories, West Grove, PA, USA); 
Alexa Fluor 488 goat anti-mouse IgG (Invitrogen, Waltham, MA, USA); peroxidase 
conjugated goat anti-mouse IgG (Jackson Immuno Research Laboratories, West 
Grove, PA, USA).  
 43 
 
 
Small molecules. Compounds for primary screens and hit validation were 
purchased from Arcos Organics (Belgium) at the purity specified by the supplier 
given in %: #9, 95%; #10, 99%; #12, 95%; #14, ≥97%; #15, ≥97%; Sigma-Aldrich 
(Taufkirchen, Germany): #3, ≥98%; #7, ≥98%; #8, 65-75%; Fluka (Taufkirchen, 
Germany): #4, ≥98%; #6 ≥97%; Aldrich (St. Louis, USA): #11, ≥95%; #13, 95%; 
Riedel-de-Haën (Seelze, Germany): #2, ≥97%. Compounds #1, ≥95% and #5, ≥95% 
were synthesized by Chiroblock GmbH (Bitterfeld-Wolfen, Germany). Compounds 
were dissolved in Dimethyl sulfoxide (DMSO) at 20 mM and stored at -20 °C. 
 
Light scattering. Experiments were performed on a Zetasizer nano (Malvern 
Instruments Ltd., Malvern, UK) in a sealed quartz cuvette using a sample volume of 
80 μl. Samples were sonicated for 10 sec in a water bath before measuring. Total 
scattering intensities were recorded over time from seven technical repetitions, each 
accumulating 30 single measurements. 
 
Dot blot assay. For dot blot assays, A42 solutions were spotted onto nitrocellulose 
membrane (Amersham Protran 0.1 µm NC, GE Healthcare Life Sciences, Munich, 
Germany). After washing the membrane with 1x PBS (13.7 mM NaCl, 0.27 mM KCl, 
1 mM Na2HPO4, 0.2 mM KH2PO4, pH 7.4), it was blocked for 30 min with 3% skim 
milk (Sigma-Aldrich, Taufkirchen, Germany) in 1x PBS containing 0.05% Tween 20 
(PBS-T). Then, the membrane was incubated over night with the primary antibody 
diluted in 3% skim milk PBS-T. Subsequently, the membrane was washed three 
times for 10 min in PBS-T and incubated with the secondary peroxidase-conjugated 
anti-mouse antibody for 1 h at room temperature. The membrane was washed two 
times for 5 min in PBS-T and two times for 10 min in PBS; immunoreactive protein 
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was detected using ChemiGlow (Biozym, Hess. Oldendorf, Germany). 
Chemiluminescence was measured with a FujiFilm LAS-3000 and images were 
quantified using the Aida image analysis software (Raytest, Straubenhardt, 
Germany). 
 
Native filter retardation assay. Samples were filtered through a cellulose acetate 
membrane with a pore size of 0.2 µm (GE Healthcare Life Sciences, Munich, 
Germany). Then, the membrane was washed with 1x PBS and blocked for 30 min 
with 3% skim milk in PBS-T. The protein aggregates retained on filter membranes 
were finally detected by antibody-based reactions as described for the dot blot 
assays.  
 
Denaturing filter retardation assay. Samples were incubated with 2% SDS and 
50 mM DTT for 5 min at 95°C and then filtered through a 0.2 µm cellulose acetate 
membrane preequilibrated in 0.1% SDS. Following, the membrane was washed with 
0.1% SDS and then used for immunodetection of aggregates as described for the dot 
blot assays.  
 
Native gels. For analysis on native gels, A42 solutions were mixed with 
NativePAGE 4x sample buffer and loaded onto a NativePAGE Novex 4-16% Bis-Tris 
gel (ThermoFisher Scientific, Waltham, MA; USA). As a molecular weight marker, the 
NativeMark unstained protein standard was used (ThermoFisher Scientific, Waltham, 
MA, USA). NativePAGE was performed according to a standard protocol. Then, 
proteins were transferred to a nitrocellulose membrane (0.45 µm; GE Healthcare Life 
Sciences, Munich, Germany) using a semi-dry Western blotting protocol. Proteins of 
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interest were detected on the membrane by an antibody-based reaction as described 
for the dot blot assays. 
 
Centrifugation experiments with A42 FAs. Preformed fibrillar A42 aggregates 
(1 μM, calculated from the molecular weight of A42 monomers) were incubated for 
24 h with 1 µM (1x) or 5 µM (5x) compound solutions in low salt buffer (LSB) at 
37 °C. As a control, the compound solvent was used. Then, the samples were 
centrifuged at 18,000 x g for 30 min at 4 °C. The supernatant was carefully removed 
and transferred to a new tube. The pellet was solubilized in LSB in a volume 
equivalent to the supernatant, vortexed and sonicated for 1 min in a sonicator bath. 
Lastly, supernatant and pellet fractions were analyzed with dot blots, filter retardation 
assays and native gels. 
 
Thioflavin T assay. A42 monomers and fibrillar aggregates (4.5 µM, monomer 
equivalent) were mixed with 20 µM Thioflavin T (ThT) in 1x PBS in a volume of 
100 µl. Fluorescence measurements of samples were performed in a plate reader 
(Infinite M200, Tecan, Männedorf, Switzerland) at an excitation wavelength of 420 
nm and an emission wavelength of 485 nm (LeVine, 1999). For kinetic 
measurements A42 monomers (10 µM) were mixed in LSB buffer with ThT (5 µM). 
Thioflavin T (ThT) fluorescence intensity measurements were performed in 
quadruplicates in black non-binding 384-well microtiter plates (Greiner Bio-One) in a 
total volume of 40 µl. The measurements were carried out every 15 min for 20 hours 
at 37 °C. Prior to each measurement the samples were shaken for 5 seconds with an 
amplitude of 2 mm. Fluorescence measurements were performed in a plate reader 
(Infinite M1000 PRO; Tecan, Männedorf, Switzerland) using the following 
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wavelengths: Ex: 440 nm/Em: 485 nm. 
 
Atomic Force Microscopy (AFM). For AFM analysis sheet mica (Glimmer V3; 
Plano, Wetzlar, Germany) were glued to a microscope slide and samples (10 μl of 
2.5 µM FA or monomer solutions, 20 µl of FAMA42 (0.05 µM)/Aβ42 (10 µM) co-
aggregation reactions) were adsorbed for 10 min onto the freshly cleaved mica, 
washed with freshly filtered deionized water (4 × 20 μl) and dried overnight. Dry AFM 
images were recorded on a Nanowizard II/Zeiss Axiovert setup (JPK) using 
intermittent contact mode and FESP silicon (Bruker AFM Probes, Camarillo, CA; 
USA) or PPP-NCHAuD probes (NANOSENSORS™, Neuchâtel, Switzerland). 
 
Homogenization of mouse brain tissues. Frozen tissue was weighed and 
homogenized in a 5-fold excess (w/v) of ice cold 50 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 0.1% SDS, 0.5% Sodium deoxycholate, 1% Triton X-100, 0.25 U/µl Benzonase 
and a complete protease inhibitor cocktail using a Schütt Homogen Plus (Schütt-
Biotec GmbH, Göttingen, Germany) semi-automatic homogenizer (700 rpm). The 
homogenate was centrifuged for 20 min at 1,500 x g at 4 °C to remove cell debris. 
The supernatant was then transferred to a new tube and the total protein 
concentration was determined with the Pierce BCA assay (ThermoFisher Scientific, 
Waltham, MA, USA) using BSA as a standard. The supernatant was analyzed by 
native filter retardation assays. Furthermore, seeding-competent A aggregate 
species were enriched by immunoprecipitation from mouse brain homogenates. 
 
Immunoprecipitation of A aggregates. Seeding-competent A aggregate species 
were enriched from mouse brain homogenates (prepared from 0.25 mg brain tissue 
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of APPPS1 transgenic mice) through immunoprecipitation with magnetic protein G 
beads (ThermoFisher Scientific, Waltham, MA, USA) coated with 6E10 or 352 
antibody, respectively. Antibody bound beads were incubated with homogenate at 
room temperature for 30 min. Beads were then washed three times in LSB before 
sonification for 30 sec with a Sonic Dismembrator Ultrasonic Processor 
(ThermoFisher Scientific, Waltham, MA, USA, FB-120, 5/64” tip). Seeding-competent 
A aggregate species (10 μl) released from beads by sonication were analyzed in FP 
assays. 
 
Western blot analysis. Protein extracts or magnetic protein G beads with 
immunoprecipitated A aggregate species were boiled with NuPAGE 4x sample 
buffer for 5 min and then loaded onto NuPAGE Novex 4-12% Bis-Tris gels 
(ThermoFisher Scientific, Waltham, MA, USA). Electrophoresis was performed 
according to a standard protocol followed by transfer of proteins onto a nitrocellulose 
membrane (0.45 µm; GE Healthcare Life Sciences, Munich, Germany) using a wet 
blotting system (BioRad, Munich, Germany). The generated blots were incubated 
with primary 6E10 (1:1000, Biolegend, San Diego, CA, USA) and HRP-conjugated 
secondary (1:2000, Sigma-Aldrich, Taufkirchen, Germany) antibodies. 
Immunoreactive proteins on membranes were visualized with WesternBright 
Quantum chemiluminescence substrate (Advansta, Menlo Park, CA, USA). 
 
MTT assay. PC12 cells were plated at a density of 15,000 cells per well on clear 96-
well plates in 90 μl fresh medium (RPMI 1640 (1x) medium supplemented with 10 % 
horse serum, 5 % FBS and 100 U/ml penicillin and streptomycin) in a 5 % (v/v) CO2 
humidified environment at 37°C. After 48 h, Aβ aggregate species were added (final 
concentration: 0.5 µM) and cells were further incubated for 1 day at 37°C. 
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Cytotoxicity was measured using an MTT assay kit (Promega). Absorbance values of 
formazan were determined at 570 nm using an Infinite spectrometer (Tecan). 
Statistical significance was assessed by one-way ANOVA followed by Dunnett's post 
hoc test. **, p≤0.01. 
 
Detection of DO1 in mouse brain tissues. This study was performed at 
Pharmacelsus GmbH (Saarbruecken, Germany). In brief, for oral administration DO1 
was freshly dissolved in an aqueous 1% methyl cellulose solution. After DO1 
administration of 10 mg per kg mouse weight with an application volume of 10 ml/kg, 
mice were perfused with PBS and sacrificed by cervical dislocation at the indicated 
time points. Brains were removed, homogenized with 1 volume of PBS using a 
Precellys Dual homogenizer (Peqlab, Erlangen, Germany) with ceramic beads. A 
volume of 20 µl of the resulting homogenate was clarified by acetonitrile (ACN, 40 µl) 
precipitation. The resulting supernatant was analyzed by LC-MS using a phenyl-hexyl 
phase (Accucore, 2.1×50 mm ID, 2.6 µm, RP159, Thermo Fisher Scientific, Dreieich, 
Germany) for separation (mobile phase A: H2O + 0.2% Heptafluorobutyric acid 
(HFBA), mobile phase B: ACN + 0.2% HFBA, % B (t (min)), 80(0-0.1)-3(0.4-1.7)-
80(1.8-2.5)) and Q-Exactive mass spectrometer (Thermo Fisher Scientific, Dreieich, 
Germany) for detection (mode: H-ESI, positive ion). Diclofenac was used as internal 
standard; for calibration spiked blank brain tissue samples were used.  
 
Quantification of GFAP with ELISA. For quantification of GFAP (glial fibrillary 
acidic protein) with ELISA, mouse brains were homogenized in 50 mM Tris-HCl pH 8 
(300 mg/ml w/v) with a complete protease inhibitor cocktail and 0.25 U/µl Benzonase 
using the Schütt Homgen Plus semi-automatic homogenizer. After 10 min incubation 
of the homogenate at 4 °C, SDS was added to a final concentration of 1.2% and 
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incubation was continued for 15 min at room temperature. Then, the homogenate 
was diluted with five volumes of ice cold 1.2% Triton X-100 and centrifuged at 
100,000 x g for 30 min to remove the insoluble material (Geumann et al., 2010). The 
supernatant was finally transferred to a new tube and protein concentration was 
determined using the Pierce™ BCA assay (ThermoFisher Scientific, Waltham, MA, 
USA). The protein BSA was utilized as a standard. The GFAP ELISA was performed 
according to standard protocols (Geumann et al., 2010). A mouse monoclonal GFAP 
antibody (concentration 500 ng/ml) and a rabbit polyclonal GFAP antibody (diluted 
1:2000) were used as capture and detection antibodies, respectively. As a protein 
standard, different concentrations of recombinant full-length human GFAP protein 
(Synaptic Systems, Göttingen, Germany) were used.  
 
Immunohistochemistry and Congo red staining. Congo red staining was 
performed as described (Wilcock et al., 2006) with slight modifications. Brain sections 
taken from cryoprotectant solution were washed three times for 5 min in PBS. The 
sections were mounted onto slides and air-dried for 20 min at room temperature. 
Slides were incubated in 0.02 M NaOH in 80% ethanol saturated with NaCl for 
20 min followed by a 45 min incubation in 0.15% (w/v) Congo red (Sigma-Aldrich, 
Taufkirchen, Germany) in 0.02 M NaOH in 80% ethanol saturated with NaCl. Stained 
sections were rinsed eight times each in 95% ethanol and 100% ethanol, followed by 
three times for 5 min incubation in Roti©-Histoclear and mounting with Roti©-Histokitt 
(Carl Roth, Karlsruhe, Germany). Primary antibodies for immunohistochemistry were 
mouse monoclonal antibodies 6E10 against human A at 1:1000 dilution and 352 
against fibrillar A oligomers at 1:1000 dilution. Secondary antibodies were: Alexa 
Fluor 488 goat anti-mouse IgG (Invitrogen, Waltham, MA, USA) at 1:2000 dilution; 
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peroxidase-conjugated goat anti-mouse IgG (Jackson Immuno Research 
Laboratories, West Grove, PA, USA) at 1:300 dilution.  
  
Assessment of amyloid load. Sections stained for Congo red positive plaques or 
A immunohistochemistry were scanned using a Nikon Super Coolscan 9000 film 
scanner (Nikon, Düsseldorf, Germany) with a gamma of 1 (Sedgewick, 2008) at 4000 
dpi. Images were exported to ImageJ for color deconvolution using the plugin 
(http://www.dentistry.bham.ac.uk/landinig/software/cdeconv/cdeconv.html) to subtract 
cresyl counterstain color. The cortex and hippocampus were manually outlined with 
the Volocity software (Perkin Elmer, Rodgau-Jügesheim, Germany); number of pixels 
and total pixel areas occupied by both structures were determined. Monochromatic-
based thresholding was used to quantify pixels occupied by Congo red-positive or 
immunolabeled plaques. The number of plaques and percentage of brain regions 
occupied by them were determined. Seven brain sections separated by 200 µm 
beginning from bregma -0.82 (Paxinos and Franklin, 2008) were evaluated for each 
mouse. The treatment status of the mice was unknown to the investigator during 
analysis.  
 
Extraction of mRNAs and quality analysis. Freshly isolated mouse brains were 
dissected and cortex was isolated. RNA was prepared from mouse tissues using the 
„RNeasy Lipid Tissue Mini Kit“ (Qiagen, Hilden, Germany). DNA was removed from 
the RNA sample using the „RNase-Free DNase Set“ kit from Qiagen (Hilden, 
Germany). The quality and yield of extracted total RNAs were analyzed on Agilent 
RNA 6000 Nano Chips by the 2100 Bioanalyzer (Agilent Technologies, Waldbronn, 
Germany) and on the NanoDrop ND-1000 UV-Vis Spectrophotometer (Thermo 
Scientific, Darmstadt, Germany).  
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RNA amplification, labeling, and hybridization. 500 ng of total RNA in 11 µl 
RNase free water was used as starting material for the generation of biotin-labeled 
cRNA with the Illumina® TotalPrep™ RNA Amplification Kit (ThermoFisher Scientific, 
Dreieich,  Germany), following supplier instructions. cRNA was cleaned up with 
cRNA filter cartridges before use for subsequent hybridization on Illumina® Sentrix 
BeadChips (Illumina, San Diego, USA). To perform whole genome expression 
analysis MouseWG-6 v2.0 Expression BeadChips, were incubated with biotin labeled 
cRNA for 18 h at 58°C in a hybridization oven under humidity-controlled conditions. 
After hybridization, the Illumina® Sentrix BeadChips were washed using buffers 
provided by the kit. 2.5 µl (1 mg/ml) of Streptavidin-Cy3 (per Chip) diluted in 2.5 ml 
blocking buffer were incubated per Chip for 10 minutes under gentle shaking 
conditions to allow binding of cRNA to gene-specific probes. After washing, Illumina® 
Sentrix BeadChips were dried and scanned using the Illumina BeadArray Reader GX 
(Illumina, San Diego, USA). To quantify gene expression signal levels we used the 
Illumina’s BeadStudio software (Illumina, San Diego, USA) package. 
 
Differential gene expression analysis. The analysis was carried out using the 
limma package in R. Probes were identified as differentially expressed for Benjamini 
and Hochberg adjusted p-value of < 0.05, and an absolute fold change > 50%. 
 
Principal component analysis (PCA). We first selected the probes that had a 
normalized value of expression above 6.5 (which is roughly the median value of 
expression in most samples) in at least 5 out of the 23 samples used in this study. 
This was done to make sure that low expression probes do not have too much of an 
impact on the PCA. This step removed 20811 of 46235 (approximately 45%) probes. 
 52 
 
The resulting filtered dataset was then mean centered and scaled so that the values 
had a standard deviation of one. The PCA was performed with these values. 
 
Ingenuity pathway analysis (IPA). The differentially expressed genes (DEGs, p < 
0.05) from the sample comparisons TGvsWT, TG*vsWT*, TG*vsWT and WT*vsWT 
were used for pathway analysis. The 10 most significant canonical pathways were 
selected using the Ingenuity Pathway Analysis (IPA) software tool 
(https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/). 
 
Quantification and Statistical Analysis 
Statistical analysis. Statistical analysis was performed using the R programming 
environment (Assenov et al., 2008; Hothorn T et al., 2017; R_Core_Team, 2006), the 
scientific data analysis software GraphPad Prism version 7.04 for Windows, 
GraphPad Software, La Jolla, California, USA, www.graphpad.com and the Student's 
t-Test of the CSBSJU Minnesota (http://www.physics.csbsju.edu/stats/t-test.html). 
Individual statistical methods are indicated in the figure legends. Statistical 
significance is indicated in the text and figure legends as *p < 0.05, **p < 0.01 and 
***p < 0.001. 
 
Data and Software Availability 
The microarray dataset contains the expression values of 23 samples tested against 
46,000 Illumina Probe IDs, of which 27,000 gave a positive signal. An MS Excel 
spreadsheet contains the values for these signals. The 23 samples are named using 
a combination of a barcode number and a letter that refers to one of the 4 groups of 
tissues from treated and untreated mice (TG+DO1, TG, WT+DO1 and WT), from 
which the samples were derived. The columns to the right of the signal values for the 
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23 samples show additional identifying information for the individual Illumina probes. 
The expression of 878 transcripts was changed significantly and used for further 
bioinformatics analyses. Another Excel spreadsheet provides detailed information for 
the 23 samples derived from mouse brains, including a reference to the 
corresponding idat files, in which the raw data are stored.  
The microarray data discussed in this publication have been deposited in NCBI's 
Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO 
Series accession number GSE119756 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE119756). 
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KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
antibody 352 This study N/A 
6E10 Biolegend Cat#803017, RRID: AB_2565327 
4G8 Biolegend Cat#800711, RRID: AB_2565324 
anti-amyloid fibrils OC antibody Merck Millipore Cat#AB2286, RRID: AB_1977024 
IgG1 ThermoFisher 
Scientific 
Cat#02-6100, RRID: AB_2532935 
anti-mouse IgG, peroxidase 
conjugated 
Sigma Cat#A0168,  
RRID: AB_257867 
mouse monoclonal GFAP antibody Synaptic Systems Cat#173011, 
RRID: AB_2232308 
rabbit polyclonal GFAP antibody Synaptic Systems Cat#173002, RRID: AB_887720 
goat anti-mouse IgG Jackson Immuno 
Research 
Laboratories 
Cat#115-005-062, RRID: AB_2338452 
peroxidase AffiniPure goat anti-
rabbit IgG 
Jackson Immuno 
Research 
Laboratories 
Cat#111-035-144, RRID: AB_2307391 
Alexa Fluor 488 goat anti-mouse 
IgG 
Invitrogen Cat#R37120, RRID: AB_2556548 
peroxidase conjugated goat anti-
mouse IgG 
Jackson Immuno 
Research 
Laboratories 
Cat#115-035-146, RRID: AB_2307392 
Chemicals, Peptides  
amyloid-β (1-42) peptide Dr. Volkmar-
Engert, Charité, 
Berlin 
custom synthesis 
amyloid-β (1-42) peptide Bachem Cat#H-1368 
GFAP protein Synaptic Systems Cat#173-OP 
5-Carboxyfluorescein labeled β-
amyloid (1-42) peptide 
Anaspec Cat#AS-23525-05 
1,1,1,3,3,3-Hexafluoro-2-propanol Sigma-Aldrich Cat#105228 
Thioflavin T Sigma-Aldrich Cat#T3516 
Pittsburgh Compound B Chiroblock GmbH custom synthesis 
Sudan Orange G Riedel-de-Haën Cat#32670 
RO 90-7501 Sigma-Aldrich Cat#R0529 
Butter Yellow Fluka Cat#73225 
RS-0406 Chiroblock GmbH custom synthesis 
Methylene Blue Fluka Cat#66720 
scyllo-Inositol Sigma-Aldrich Cat#I8132 
Tramiprosate Acros Organics Cat#104430010 
Azobenzene Acros Organics Cat#401540050 
Orange GS Aldrich Cat#S472646 
Disperse Orange 3 Acros Organics Cat#201620500 
Disperse Red 1 Aldrich Cat#344206 
4-(Phenylazo)diphenylamine Acros Organics Cat#21210250 
Key Resource Table
 Disperse Orange 1 (DO1) Acros Organics Cat#199410500 
Congo red Sigma-Aldrich Cat#C6277 
Biological Samples 
APPPS1 mouse brain Dr. Frank  
Heppner (Charité, 
Berlin) 
N/A 
5xFAD mouse brain This paper N/A 
Critical Commercial Assays 
nitrocellulose membrane, 0.1 µm  
(Dot blot assay)  
GE Healthcare Cat#10600000 
nitrocellulose membrane, 0.45 µm 
(Western blot) 
GE Healthcare Cat#10600002 
cellulose acetate membrane, 
0.2 µM (Native filter retardation 
assay) 
GE Healthcare Cat#10404180 
NativePAGE Novex 4-16% Bis-Tris 
gel 
ThermoFisher 
Scientific 
Cat#BN1004BOX 
NuPAGE Novex 4-12% Bis-Tris ThermoFisher 
Scientific 
Cat#NP0323BOX 
Mica Plano Cat#G-250-2 
CellTiter 96® Non-Radioactive Cell 
Proliferation Assay (MTT) 
Promega Cat#G4000 
ChemiGlow Biozym Cat#541015 
Illumina™ TotalPrep™ RNA 
Amplification Kit 
ThermoFisher 
Scientific 
Cat#AMIL1791 
Deposited data 
Raw and analysed microarray data This paper GEO: GSE119756 
(https://www.ncbi.nlm.nih.gov/geo/query/ 
acc.cgi?acc= GSE119756) 
Experimental Models: Organisms/Strains 
5xFAD mice The Jackson 
Laboratory 
MMRRC Stock No: 34840-JAX,  
RRID: MMRRC-034840-JAX 
BL6SJLF1/J mice The Jackson 
Laboratory 
Stock No: 100012, RRID: IMSR_JAX:100012 
Software and Algorithms 
R version 3.4.0 R Development 
Core Team, 2006 
https://www.r-project.org/ 
Beadarray (R package) Dunning et al., 
2007 
https://bioconductor.org/packages/ 
release/bioc/html/beadarray.html 
ArrayQualityMetrics (R package) Kauffmann et al., 
2009 
https://bioconductor.org/packages/ 
release/bioc/html/arrayQualityMetrics.html 
Limma (R package) Ritchie et al., 2015 https://bioconductor.org/packages/ 
release/bioc/html/limma.html 
Ingenuity Pathway Analysis (IPA) Kramer et al., 2014 https://www.qiagenbioinformatics.com/ 
products/ingenuity-pathway-analysis/ 
Student's t-Test CSBSJU 
Minnesota 
http://www.physics.csbsju.edu/stats/t-
test.html 
Other 
Standard protocol for antibody 
production 
Synaptic Systems https://www.sysy.com/services/index.php 
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Figure S1 (related to Figure 1). Biochemical characterization of preformed A42 
seeds. 
(A) Thioflavin T (ThT) fluorescence (arbitrary units, AU) and fluorescence polarization 
(milli-polarization, mP) were measured over time in spontaneous polymerization 
reactions. ThT and FP values were recorded at 440/485 and 470/528 nm, respectively. 
ThT and FP assays were performed in quadruplicates. The results of one experiment 
are shown (mean ± SD). (B) ThT fluorescence measurement of preformed A42 
fibrillar aggregates (FAs; 4.5 M monomer equivalents) and monomers (4.5 M) 
measured in arbitrary units (AU). Data represent mean ± SD. Average values were 
derived from triplicates of each sample. (C) Analysis of preformed A42 FAs and 
monomers by atomic force microscopy using FESP silicon probes. Color gradient: 0-
20 nm height.  
Figure S2 (related to Figure 1). Analysis of compound effects on seeded and 
non-seeded FAMA42/ A42 co-aggregation with FP assays. 
(A) Effects of potential aggregation modulators from the literature (#1 - #9, 1 µM) on 
seeded and non-seeded FAMA42/A42 co-polymerization (10 µM; black: A42 with 
seeds; blue: A42 w/o seeds; violet: A42 with seeds and compound; red: A42 with 
compound and w/o seeds). (B) Effects of azo compounds #10 - #15 (1 µM) on seeded 
and non-seeded FAMA42/A42 co-aggregation reactions (10 µM; black: A42 with 
seeds; blue: A42 w/o seeds; violet: A42 with seeds and compound; red: A42 with 
compound and w/o seeds). (C) Quantification of the inhibitory effect of compounds on 
seeded FAMA42/A42 co-aggregation. The inflection point (IP1) of the seeded but 
untreated aggregation curve was set at zero; the time shift of the corresponding 
inflection point (IP2) of the compound-treated seeded aggregation reactions was 
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expressed as Δ-value in hours. (D) Summary of the inhibitory effects of the tested 
compounds #2, #4, #10 - #14 and #15/ DO1 on seeded A42 aggregation expressed 
as shift of the inflection points. Data in A and B represent mean ± SD. 
Figure S3 (related to Figure 2). Analysis of A42 fibrillar assembles (FAs) and 
monomers in DBAs using the antibodies 352, 6E10, 4G8 and OC. 
DBAs revealed that the monoclonal antibody 352 detects preformed A42 FAs but not 
monomers. In comparison, both FAs and monomers were recognized by the antibodies 
OC (A), 6E10 and 4G8 (B). Staining of membranes with amido black confirmed that 
similar amounts of A42 monomers and FAs were analyzed. In (A) 120 ng of FAs and 
monomers were immobilized on membrane. (C, D) Box plot quantification of DBAs 
shown in Figure 2A, main text. (C) Quantification of 6E10 and (D) of 4G8 
immunoreactivities. Two-way analysis of ANOVA showed a significant DO1 treatment 
effect (F (2,18) = 15.39, p = 0.000127) and position (antibody reactivity in pellet versus 
supernatant) effect (F (1,18) = 64.88, p = 2.22e-07) for 6E10 DBAs. There was also a 
significant interaction between treatment and position effects (F (2,18) = 83.41, p = 
7.88e-10). For 4G8, the two-way ANOVA analysis revealed a treatment effect of 
F(2,18) = 6.97, p=0.00573; a position effect of F(1,18) = 22.85, p = 0.00015; and an 
interaction between treatment and position effects F(2,18) = 84.90, p = 6.83e-10. 
Figure S4 (related to Figure 3). Effects of DO1 on seed-mediated amyloid 
assembly. 
(A) AFM analysis of aggregate species derived from seed-mediated FAM-Aβ42 (0.05 
µM)/Aβ42 (10 µM) co-aggregation reactions after incubation of samples for 18h. Color 
gradient: 0-10 nm height, except for the sample with 5 µM DO1 where the height is 0-
8 nm. Samples were analyzed using the AFM probe PPP-NCHAuD. (B) Quantification 
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of oligomers in seeded A42 aggregation reactions shown in A. Oligomers were 
counted in three different areas (0.5 x 0.5 µm each) of the respective AFM pictures 
shown in A. Data show mean ± SEM. *** p<0.001, ** p<0.01, one-way ANOVA. (C) 
Effects of different concentrations of DO1 on the seeding activity of A species 
immunoprecipitated from APPPS1 mouse brain homogenates using the 352 anti-A 
antibody (352-IP; see Figure 3E main text). As a control IgG1 immunoprecipitates 
(IgG1-IP) were tested that show no seeding activity. Average values were derived from 
quadruplicates of each sample in the experiment. Data represent mean ± SD. 
Figure S5 (related to Figure 4). Effects of DO1 on A aggregation and GFAP 
levels in brains of AD transgenic mice.  
(A) Assessment of the DO1 concentration in mouse brains. The DO1 concentration 
was determined after a single administration by oral gavage. 10 mg DO1 per kg mouse 
weight were applied; mouse brain extracts were analyzed by LC-MS. Per time point 
three male mice were used. Data represent mean ± SD. (B-E) Effects of DO1 treatment 
on A plaque load in cortex of 5xFAD transgenic mice. (B) Immunohistochemical 
detection of A plaques in the cortex of 5xFAD female mice treated for 8 months with 
0.652 g DO1 per kg of mouse chow. Top and middle rows, 3,3'-diaminobenzidine 
(DAB) staining of A plaques with 352 and 6E10 antibodies. Bottom rows, Congo red 
staining of dense core regions in A plaques. DO1 treatment of 5xFAD mice 
significantly reduced 352 (C) and 6E10 (D) immunoreactivities (***p < 0.001 versus 
control, one-way ANOVA, n = 4-5 mice per group). (E) Quantification of Congo red 
stained dense core plaque regions of compound treated and untreated animals. Scale 
bar in B = 50 µm and applies to all images. Data represent mean ± SEM. (F-H) DO1 
treatment decreases the abundance of A aggregates and reduces GFAP levels in 
brains of AD transgenic mice. (F) Analysis of 352-reactive A aggregates in brain 
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homogenates, prepared from hemispheres of 7.5 month-old DO1 treated and 
untreated (ctrl) male 5xFAD transgenic (Tg) mice by native filter retardation assays 
(FRAs). Brain homogenates of wild-type (Wt) DO1 treated and untreated mice were 
analyzed as control. Similarly, we assessed homogenates of treated and untreated AD 
transgenic mice. (G) Quantification of results shown in F. Data represent mean ± SD 
(**p < 0.01, unpaired two tailed t-test). (H) Analysis of GFAP protein levels in brain 
homogenates, prepared from hemispheres of 9.5 month-old DO1-treated and 
untreated 5xFAD female transgenic (Tg) and wild-type (Wt) mice (Wt ctrl n = 5, Tg ctrl 
n = 6, Wt DO1 n = 9, Tg DO1 n = 10) by ELISA (***p < 0.001, one-way ANOVA). Data 
represent mean ± SEM. 
Figure S6 (related to Figure 6). IPA pathway analysis.  
Presented are the top ten significantly (p < 0.05) dysregulated pathways obtained with 
the datasets: (A) TGvsWT, (B) TG*vsWT*, (C) TG*vsWT and (D) WT*vsWT. 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
#1           Pittsburgh Compound B
               (2-(4-(Methylamino)phenyl)benzo[d]thiazol-6-ol)
 
#2            Sudan Orange G
                (4-(Phenyldiazenyl)benzene-1,3-diol)  
#3            RO 90-7501
                    (2'-(4-aminophenyl)-1H,1'H-2,5'-bibenzo[d]imidazol-5-amine) 
#4            Butter Yellow
      
                 (N,N-Dimethyl-4-(phenyldiazenyl)aniline)
#5            RS-0406 
                 (3,3'-(Pyridazine-3,6-diylbis(azanediyl))diphenol)
#6            Methylene Blue
                (N-(7-(Dimethylamino)-3H-phenothiazin-3-ylidene)-N-methylmethanaminium chloride)   
#7            scyllo-Inositol
    
                 ((1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexaol)
#8            Thioavin T
                    (2-(4-(Dimethylamino)phenyl)-3,5-dimethylbenzo[d]thiazol-3-ium chloride) 
#9            Tramiprosate
                (3-Aminopropane-1-sulfonic acid)
#10          Azobenzene 
                    (1,2-Diphenyldiazene)
#11          Orange GS
      
                (Sodium 4-((4-(phenylamino)phenyl)diazenyl)benzenesulfonate)   
#12          Disperse Orange 3 
        
                (4-((4-Nitrophenyl)diazenyl)aniline)
#13          Disperse Red 1
                (2-(Ethyl(4-((4-nitrophenyl)diazenyl)phenyl)amino)ethanol)
#14          4-(Phenylazo)diphenylamine
                (N-Phenyl-4-(phenyldiazenyl)aniline)
#15          Disperse Orange 1 (DO1)
                (4-((4-Nitrophenyl)diazenyl)-N-phenylaniline)         
Table S1 (related to Figures 1 and 2)
No.      Trivial name/ Code                                                                    Structure
            ( )IUPAC Nomenclature
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Table S1 (related to Figures 1 and 2). Overview of tested chemical compounds 
using the FP assay.  
The list of small molecules contains known amyloid aggregate binders as well as 
compounds that have not previously been shown to interact with amyloid structures. 
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